Effect of ethosuximide on rest tremor in the MPTP monkey model.
Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor. After 5 days of daily treatment, the tremor was reduced by 60%. Diltiazem and verapamil which act on different calcium channels had no such effect. Ethosuximide also potentiated the anti-tremor effect of the dopamine D2 agonist LY-171555.
Gomez-Mancilla
B
B
Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, Canada.
Latulippe
J F
JF
Boucher
R
R
Bédard
P J
PJ
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D004110:Diltiazem / Q000008:administration & dosage; D015259:Dopamine Agents / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004576:Electromyography / Q000187:drug effects; D004873:Ergolines / Q000008:administration & dosage; D005013:Ethosuximide / Q000008:administration & dosage* / Q000633:toxicity; D005260:Female; D008252:Macaca fascicularis; D009460:Neurologic Examination / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D019257:Quinpirole; D014202:Tremor / Q000139:chemically induced / Q000188:drug therapy; D014700:Verapamil / Q000008:administration & dosage
D015259:Dopamine Agents; D004873:Ergolines; D019257:Quinpirole; D005013:Ethosuximide; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014700:Verapamil; D004110:Diltiazem